Letters to the Editor
Imiquimod to Treat Basal Cell and Squamous Cell Carcinomas
Am Fam Physician. 2005 Jul 1;72(01):41.
to the editor: It was good to see the review article1 of basal cell and squamous cell carcinomas. Please note that, since this article was written, imiquimod 5% cream (Aldara) has received approval by the U.S. Food and Drug Administration for the treatment of some types of actinic keratoses and basal cell cancers. It is specifically indicated for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults, with a maximum tumor diameter of 2 cm.2
1. Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinomas. Am Fam Physician. 2004;70:1481–8.
2. Aldara [package insert]. St. Paul, Minn.: 3M Pharmaceuticals, 2004.
editor’s note: 3M Pharmaceuticals manufactures imiquimod.
Send letters to email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions